Table 2.
Age (Years) | ≤29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥80 |
---|---|---|---|---|---|---|---|
Fluoropyrimidine lines of chemotherapy | |||||||
DM+ (days) | - | - | 109 | 118 | 150 | 90 | 52 |
DM− (days) | 66 | 118 | 124 | 119 | 127 | 132 | 123 |
Oxaliplatin lines of chemotherapy | |||||||
DM+ (days) | - | - | 23 | 95 | 142 | 77 | - |
DM− (days) | 144 | 161 | 129 | 101 | 93 | 99 | 70 |
Irinotecan lines of chemotherapy | |||||||
DM+ (days) | - | - | 200 | 157 | 176 | 103 | 81 |
DM− (days) | 28 | 90 | 120 | 119 | 129 | 150 | 131 |
Bevacizumab/Aflibercept lines of chemotherapy | |||||||
DM+ (days) | - | - | 196 | 81 | 140 | 103 | - |
DM− (days) | 42 | 159 | 178 | 171 | 178 | 162 | 88 |
Cetuximab/Panitumumab lines of chemotherapy | |||||||
DM+ (days) | - | - | 31 | 137 | 239 | 215 | 78 |
DM− (days) | 64 | 129 | 134 | 107 | 171 | 140 | 100 |